- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: DBT.
Displaying page 1 of 1.
EudraCT Number: 2022-001175-14 | Sponsor Protocol Number: BHV3000-406 | Start Date*: 2023-04-17 | |||||||||||
Sponsor Name:Biohaven Pharmaceuticals, Inc. | |||||||||||||
Full Title: BHV3000-406: A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use | |||||||||||||
Medical condition: migraine attacks with or without aura | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) AT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001176-34 | Sponsor Protocol Number: BHV3000-407 | Start Date*: 2023-02-20 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: BHV3000-407: A Phase 4, Randomized, Doubleblind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults with a History of Inadequa... | |||||||||||||
Medical condition: migraine headaches with or without aura | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) IT (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003699-38 | Sponsor Protocol Number: CEDM-MRI | Start Date*: 2021-04-28 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | |||||||||||||
Full Title: DETECTION RATE AND CLASSIFICATION OF BREAST LESIONS WITH DIGITAL MAMMOGRAPHY WITH CONTRAST MEDIUM (CEDM) ALONE AND IN COMBINATION WITH TOMOSYNTHESIS COMPARED TO MR IMAGING WITH GADOLINIUM IN DYNAMI... | |||||||||||||
Medical condition: Breast souspicious lesions | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000893-69 | Sponsor Protocol Number: BN42082 | Start Date*: 2020-10-28 | ||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS | ||||||||||||||||||||||||||||
Medical condition: Relapsing Multiple Sclerosis (MS) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) NL (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000894-26 | Sponsor Protocol Number: BN42083 | Start Date*: 2020-10-12 | |||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||
Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPL... | |||||||||||||||||||||||
Medical condition: Primary Progressive Multiple Sclerosis (MS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003919-53 | Sponsor Protocol Number: GN41791 | Start Date*: 2020-09-23 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PR... | |||||||||||||
Medical condition: Primary Progressive multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Ongoing) DE (Trial now transitioned) PT (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001511-73 | Sponsor Protocol Number: WA40404 | Start Date*: 2019-12-23 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A PHASE IIIb MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | ||
Medical condition: | ||
Disease: | ||
Population Age: | Gender: | |
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) PT (Trial now transitioned) IE (Completed) DE (Ongoing) BG (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) HU (Completed) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004857-10 | Sponsor Protocol Number: GN41851 | Start Date*: 2020-11-20 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSIN... | ||||||||||||||||||
Medical condition: Relapsing multiple sclerosis (RMS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Trial now transitioned) NL (Ongoing) DE (Trial now transitioned) PT (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001168-28 | Sponsor Protocol Number: GN42272 | Start Date*: 2020-12-21 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSIN... | ||||||||||||||||||
Medical condition: Relapsing multiple sclerosis (RMS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) BG (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005239-22 | Sponsor Protocol Number: BHV3000-404 | Start Date*: 2022-06-20 | |||||||||||||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||||||||||||
Full Title: A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens | |||||||||||||||||||||||
Medical condition: Acute Migraine (with or without aura) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) AT (Ongoing) FR (Completed) SE (Completed) IT (Completed) PL (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020956-69 | Sponsor Protocol Number: OX02 | Start Date*: 2011-02-23 | ||||||||||||||||
Sponsor Name:Universitätsklinikum Freiburg | ||||||||||||||||||
Full Title: Effekte von Oxytocin bei Patientinnen und Patienten mit Borderline-Persönlichkeitsstörung | ||||||||||||||||||
Medical condition: ICD-10 F60.3 Emotionally unstable personality disorder Two types may be distinguished: the impulsive type, characterized by emotional instability and lack of impulse control, and the borderline typ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
